Newsletter
ZURICH, Switzerland/CHARLOTTE, N.C., USA: US health care conglomerate Danaher is proceeding with its acquisition of Nobel Biocare shares. The offer period of the public tender offer of Danaher Corporation for all publicly held registered shares of Nobel Biocare expired on 14 November, and Danaher has now released the provisional interim results. A total of 72,001,022 Nobel Biocare shares were tendered under the offer during the offer period.
This corresponds to 60.97 per cent of the 118,095,706 Nobel Biocare shares to which the offer relates. At the end of the offer period, Danaher and the persons acting in concert with Danaher held a total of 97,196,634 Nobel Biocare shares (78.52 per cent of all listed Nobel Biocare shares), including the 5,688,824 shares held by Danaher and the persons acting in concert with Danaher on 26 September, as well as the 19,506,788 shares acquired by Danaher and the persons acting in concert with Danaher outside the offer.
More than 67 per cent of all issued Nobel Biocare shares (a requirement of Danaher’s key offer conditions) were tendered by the end of the offer period.
Danaher has confirmed that, if all relevant conditions are fulfilled, the additional acceptance period for the offer will start on 21 November and is expected to last until 4 December. The board of directors of Nobel Biocare recommends to its shareholders to accept the offer.
From http://www.dental-tribune.com
